A scan study of PSMA in glioblastoma during bevacizumab treatment
Official title: The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study uses a special scan to look at brain tumors in people taking bevacizumab.
Read our full plain-language summary
What the trial team says
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
Key facts
- Registry number
- NCT07052877
- Conditions studied
- Glioblastoma, Glioblastoma Multiforme (GBM)
Where it is running
This trial lists 1 site.
-
New South Wales
- Royal North Shore Hospital (Saint Leonards)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.